. Author manuscript; available in PMC: 2021 Aug 10.

Published in final edited form as: Int Arch Allergy Immunol. 2020 Aug 10;181(11):879–887. doi: 10.1159/000509600

Table 3.

Linear regression models for the effect of BPS on FEV₁ (% predicted), RV/TLC (% predicted) at baseline, or FEV1 change (% predicted) after intramuscular triamcinolone acetonide (TA) administration

	FEV₁ (% predicted)		RV/TLC (% predicted)		FEV₁ (% predicted) change after TA

Model	β (95% CI)	p	β (95% CI)	p	β (95% CI)	p
Unadjusted	−6.1 (−10.4, −1.8)	0.007	6.0 (2.2, 9.9)	0.003	−1.4 (−3.5, 0.6)	0.17
Adj. for age and severity	−6.1 (−9.9, −2.2)	0.003	5.7 (1.9, 9.5)	0.004	−1.8 (−3.8, 0.2)	0.09
Adj. for age, severity, FEV₁	-		1.2 (−1.5, 3.8)	0.40	−2.6 (−4.6, −0.4)	0.02

β estimate for the association with BPS showing the amount of difference in a lung function variable or in the FEV₁ change variable that would be expected for a 1 SD (15 ng/ml) increase in BPS, n = 62 (with complete RV/TLC data) for FEV₁ and RV/TLC, 55 for FEV₁ change. FEV₁ = pre-bronchodilation FEV₁. With n = 70, β was −6.9 (−11.3, −2.5), p = 0.002, for FEV₁. Adj., adjusted; BPS, baseline P-selectin; CI, confidence interval; FEV₁, forced expiratory volume in 1 s; r_s, Spearman rank correlation coefficient; RV, residual volume; TLC, total lung capacity.